about
A hyperdynamic portal syndrome with ascites after endoscopic laser treatment.Acute renal failure in Plasmodium malariae infection.L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-α 2b plus ribavirin.Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement.Acetyl L-carnitine (ALC) treatment in elderly patients with fatigue.A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in ItalyRelationship between circulating interleukin-10 and histological features in patients with chronic C hepatitisRosuvastatin reduces nonalcoholic fatty liver disease in patients with chronic hepatitis C treated with α-interferon and ribavirin: Rosuvastatin reduces NAFLD in HCV patients.Carotid intima-media thickness and liver histology in hemodialysis patients with nonalcoholic Fatty liver disease.Gordon's syndrome: a case report.Plasma erythropoietin levels in anaemic and non-anaemic patients with chronic liver diseasesA study of cupremia in a group of elderly diabetics.[Type 4 renal tubular acidosis caused by spironolactone. A case report]Effects of antioxidants on postprandial oxidative stress and endothelial dysfunction in subjects with impaired glucose tolerance and type 2 diabetes.Efficacy of human recombinant erythropoietin plus IFN-alpha in patients affected by chronic hepatitis C.Duration of menopause and behavior of malondialdehyde, lipids, lipoproteins and carotid wall artery intima-media thickness.Oxidative stress and endothelial damage in patients with asymptomatic carotid atherosclerosis.Plasma endothelin-1 levels and albumin excretion rate in normotensive, microalbuminuric type 2 diabetic patients.An unusual case of genodermatosis with familial gastrointestinal polyposis, angiomatous malformation and ascites.L-carnitine decreases severity and type of fatigue induced by interferon-alpha in the treatment of patients with hepatitis C.Hyperhomocysteinemia in preeclampsia is associated to higher risk pressure profiles.Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: comparison between interferon-alpha-2a and interferon-alpha-2b.Isomorphic response in eruptive xanthomas.Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor.Current status of implementation of self-administration training in various regions of Europe, Canada and the USA in the management of hereditary angioedema.Behaviour of some indicators of oxidative stress in postmenopausal and fertile women.Effects of antioxidant supplementation on postprandial oxidative stress and endothelial dysfunction: a single-blind, 15-day clinical trial in patients with untreated type 2 diabetes, subjects with impaired glucose tolerance, and healthy controls.[A case of overlap syndrome: autoimmune idiopathic hepatitis/pulmonary idiopathic hypertension]Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.An unusual case of post-transfusion malaria.Oxidative stress, nitric oxide, endothelial dysfunction and tinnitus.The supplementation of acetyl-L-carnitine decreases fatigue and increases quality of life in patients with hepatitis C treated with pegylated interferon-α 2b plus ribavirin.Unusual manifestations of hereditary angioedema.Patients with unrecognized peripheral arterial disease (PAD) assessed by ankle-brachial index (ABI) present a defined profile of proinflammatory markers compared to healthy subjects.[HAV infection in patients with chronic hepatitis C]Meaning of elevated CA 19-9 serum levels in chronic hepatitis and HCV-related cirrhosis.Endothelin-1 and endothelial damage in elderly patientsTinnitus and oxidative stress in a selected series of elderly patientsA nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in ItalyPlasma Levels of Inflammatory Biomarkers in Peripheral Arterial Disease
P50
Q31106134-5AF7906C-26DA-4256-BE53-7FFDFC91C36EQ33379341-3D1A8080-CBEE-43E0-8398-F77B5FBCDCF7Q33398403-FBD848F2-1B80-4C57-9B79-25D881559FD5Q34293132-7BD498B1-E2A8-4E13-AB04-E6ECDB756B65Q34656722-3AB67058-0BE9-4D54-9EAA-E354DCDEA64DQ35099643-C9AEDC75-97A6-4C2D-B8E2-190090AA2D16Q35165793-094A6329-23CA-47BE-805E-B83DD9AE0DD2Q35507354-76CA82F5-0A1A-469B-8B34-48EADDEEF6ECQ35902576-B27003E2-9678-4B6D-B20E-E089225E40DAQ35956392-CD0313FC-C317-4D9F-92FB-C051420E232DQ36213861-9FA72588-1EDD-4183-A471-99F5BD286385Q41606441-F64D9559-CC20-4F15-94CD-7F563EB5BC50Q42549618-AE421B10-3392-44D5-B9FB-C10FA0B20CD6Q43137796-DAFFC27C-F518-4F0A-8B94-C7E4FAA27804Q43541359-55C5B76D-A073-4C0D-9611-0498F8663100Q43672787-2726AA2B-ECBE-494C-972C-4DB0415DD522Q43684045-8F30661A-46F3-4DFB-84A2-FD2C92E0826CQ44080388-5014F256-AF93-4504-A3D7-6A028FF98809Q44081247-F3588848-3CEC-44EE-901C-1BC5129644FAQ44411600-95A43E13-6580-477E-B070-16E72BE7F9E3Q44676826-8587A3A9-624F-4023-9543-3E3DFF30D410Q44819674-01F5CB84-5B01-4375-954D-4ADF0F839CC0Q44966427-2DF90C2C-78F7-4B06-838B-129136FCC6C3Q45055352-3B9B7D46-5109-463D-8874-649FEA3EDABEQ45893080-C50EEBA1-947E-482A-A62C-11060F90A809Q46833402-B1CA24D9-4C37-42A0-B7BC-2D38101A5701Q46861509-160BFB0E-50F4-4221-9652-0ECEE8ACDB14Q46937863-976E4BD3-0608-4695-B544-245BF67AA8C6Q46948629-119A28A0-1C57-4EC2-B5E7-509F495E2865Q47836677-7BE1D6D5-DCB9-437C-A728-8D91D17862E2Q48509826-C4BD4EB2-C040-4AD9-811E-9AE8C6EC1049Q48590661-9B0858F3-F0A4-41C4-B5F8-399E016FE4A8Q49129382-005923C8-AEAE-41B3-8409-92AD068274ACQ49203352-D8012B20-94F5-42F3-B2C5-C60F2FF145C3Q50571414-C149C65A-2D49-4BED-9576-236A030E24C9Q53450715-63316821-19C6-4421-9290-D3E0F5B456AEQ59388233-2D993AC8-FB95-4E93-9732-DA6E62AE4F83Q59388243-A7957CB6-918F-4DE5-86FC-0BD056964553Q59403590-C1467F8B-68C4-4FC7-AA73-3D7B3F9D707CQ60981571-B0E0F25D-F29E-4513-8480-68933EEC1DA1
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0001-9314-8554
@en
name
Sergio Neri
@ast
Sergio Neri
@en
Sergio Neri
@es
Sergio Neri
@nl
type
label
Sergio Neri
@ast
Sergio Neri
@en
Sergio Neri
@es
Sergio Neri
@nl
prefLabel
Sergio Neri
@ast
Sergio Neri
@en
Sergio Neri
@es
Sergio Neri
@nl
P106
P1153
7005585400
P21
P31
P496
0000-0001-9314-8554